IMARC Group has recently released a new research study titled “United States Digital Pathology Market Size, Share, Trends and Forecast by Product, Type, Delivery Model, Application, End User, and Region, 2025-2033” which offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

Market Overview

The United States digital pathology market size was valued at USD 347.48 Million in 2024 and is expected to reach USD 853.47 Million by 2033. The market is estimated to grow at a CAGR of 9.70% during the forecast period 2025-2033. Growth is driven by increasing demand for accurate diagnosis, rising telepathology adoption for remote consultations, advancements in AI-driven image analysis, improved workflow efficiency, and supportive government initiatives promoting digital healthcare infrastructure.

Study Assumption Years

• Base Year: 2024

• Historical Year/Period: 2019-2024

• Forecast Year/Period: 2025-2033

United States Digital Pathology Market Key Takeaways

• Current Market Size: USD 347.48 Million in 2024

• CAGR: 9.70% (2025-2033)

• Forecast Period: 2025-2033

• Increasing cancer and chronic disease cases drive demand for precise diagnosis and pathology services.

• AI-powered whole-slide imaging and high-resolution scanners enhance diagnostic capabilities and workflow efficiency.

• Telepathology adoption accelerates remote consultations facilitated by enhanced internet connectivity and secure cloud platforms.

• Pharmaceutical companies use digital pathology to expedite clinical trials and drug discovery.

• Shift toward value-based healthcare motivates providers to improve diagnostic accuracy, efficiency, and personalized treatment.

Sample Request Link: https://www.imarcgroup.com/united-states-digital-pathology-market/requestsample

United States Digital Pathology Market Growth Factors

The United States digital pathology market growth is witnessing strong, driven by the rising need for faster, more accurate diagnostic solutions. Increasing patient volumes—particularly cancer cases—require detailed pathological analysis, and digital pathology enables high-resolution slide scanning for rapid interpretation and shorter turnaround times. AI-powered tools further enhance efficiency by automating image analysis, identifying patterns, and prioritizing critical cases, thereby reducing human error and improving diagnostic accuracy. As a result, hospitals and laboratories are increasingly adopting digital pathology solutions to optimize workflows, especially in pathology-intensive departments.

Growth in drug development and biomedical research is also accelerating market adoption. Pharmaceutical companies, biotechnology firms, and academic institutions rely on digital pathology for preclinical research, clinical trials, and biomarker discovery. Advanced imaging combined with AI capabilities enables faster tissue analysis, consistent results, and improved collaboration across research teams, including international partnerships. Notably, the 2024 launch of the Prov-GigaPath AI model by Microsoft, the University of Washington, and Providence highlights advancements in cancer diagnosis by enabling predictions of gene mutations, tumor subtypes, and treatment responses.

Additionally, the rising prevalence of cancer and chronic diseases remains a major driver of market expansion. Digital pathology allows pathologists to efficiently analyze complex tissue samples using advanced imaging and AI-based analytics, supporting timely and accurate diagnoses. Healthcare facilities are leveraging these digital solutions to manage growing workloads, reduce diagnostic delays, and improve patient outcomes. Strategic collaborations, such as the partnership between Alverno Laboratories and Ibex Medical Analytics, are further enhancing diagnostic accuracy and productivity through AI-driven pathology solutions, strengthening overall quality of patient care.

United States Digital Pathology Market Segmentation

Breakup by Product:

• Scanners: Facilitate conversion of glass slides into high-resolution digital images, essential for diagnostics and research. Advancements in scanning speed, throughput, and resolution drive adoption.

• Software: Provides tools for image management, analysis, and sharing. AI-powered automation enhances diagnostic accuracy and workflow efficiency.

• Storage Systems: Support large volumes of high-resolution images with secure and scalable solutions, including growing use of cloud storage.

• Communication Systems: Enable data exchange and remote collaboration among pathologists and healthcare professionals, supporting telepathology.

Breakup by Type:

• Human Pathology: Dominates market, driven by chronic diseases and cancer diagnostics; enhanced by AI tools and telepathology for remote collaboration.

• Veterinary Pathology: Growing steadily with digital adoption in animal diagnostics, improving efficiency and disease management.

Breakup by Delivery Model:

• On-premises: Preferred for data control and regulatory compliance, suited for large labs and healthcare facilities requiring privacy and performance.

• Hosted: Cloud-based solutions gaining traction for flexibility, cost-effectiveness, and remote access, favored by smaller labs and research institutions.

Breakup by Application:

• Training and Education: Digital slides enable interactive learning and case sharing, enhancing pathology education.

• Consulting Services: Facilitate expert collaboration and second opinions, aiding diagnosis of complex and rare cases.

• Intraoperative Consultation: Provides rapid tissue analysis during surgeries, improving accuracy and surgical outcomes.

• Routine Diagnostic Consultation Services: Largest segment, streamlining pathology workflows and enhancing accuracy, supported by AI-based identification of abnormalities.

• Others: Include research, clinical studies, and drug discovery, leveraging digital pathology for data evaluation and collaboration.

Breakup by End User:

• Pharmaceutical and Biotechnology Companies: Use digital pathology for drug discovery, clinical trials, and biomarker research, accelerating therapeutic development.

• Hospitals and Reference Laboratories: Employ digital solutions to improve diagnostic accuracy, workflow efficiency, and enable remote consultations.

• Academic and Research Institutes: Utilize digital pathology for education, research, image sharing, and collaboration to advance disease understanding and drug development.

Regional Insights

The Northeast is a dominant region in the United States digital pathology market, driven by its concentration of advanced healthcare systems, renowned academic centers, research institutions, and biotechnology companies. High investments support deployment of advanced digital pathology tools, improving diagnostic accuracy and patient care. This region leads in innovation and adoption, contributing significantly to market growth. The Midwest, South, and West also show increasing adoption, each propelled by healthcare infrastructure enhancements, research initiatives, and technology hubs.

Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=20357&flag=C

Recent Developments & News

In June 2024, NYU Langone Health launched a digital pathology program transitioning from microscopes to high-definition, shareable images to speed and improve disease diagnosis, integrating AI to address pathologist shortages and enhance patient care. In the same month, Sectra introduced a genomics IT module for molecular pathology with the University of Pennsylvania Health System, enabling cancer diagnostics based on genomic data and personalized treatment planning. This solution integrates with medical records, reducing IT burdens and advancing precision care.

Competitive Landscape

Major participants focus on AI-powered diagnostic solutions, advanced imaging, and cloud-based systems to boost precision and efficiency. Investments in R&D aim to incorporate AI for automated image assessment and stronger workflows. Companies expand via strategic alliances, acquisitions, and collaborations with healthcare providers and laboratories. In 2024, Sectra and Leica Biosystems obtained FDA clearance for using DICOM images in pathology diagnostics, supporting standardization and interoperability.

Key Players

• Sectra

• Leica Biosystems

• Proscia

• Microsoft

• University of Washington

• Providence

• Alverno Laboratories

• Ibex Medical Analytics

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world's most changemakers to create a lasting ambitious impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302